Bonnee Binker and Paul Motenko to lead efforts in Washington, D.C., for volunteer conference, teamMATEs: Together Until It's Done.
Site Search
Showing 141 - 150 of 564 results
News
|
Jan. 27, 2011
|
2 min read
News
|
Jan. 19, 2010
|
2 min read
News
|
May 17, 2010
|
3 min read
News
|
Dec. 12, 2017
|
3 min read
Foundation and Legislative Supporters Pushed for Bill
Press Release
|
April 29, 2008
|
3 min read
Press Release
|
July 16, 2008
|
5 min read
The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
News
|
Aug. 1, 2017
|
2 min read
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
News
|
May 17, 2017
|
3 min read
The American Thoracic Society (ATC) Calls CFF.org “Outstanding” and a “Must Book-mark Site”
Press Release
|
Jan. 14, 2009
|
3 min read
Vestavia Hills High School Raises More than $17,000 and Beats Schools Nationwide
Press Release
|
May 5, 2009
|
2 min read